Can I Take Vitamin D with NMN or NR (Nicotinamide Mononucleotide / Riboside)?

What Is NMN and NR, and Why Do People Take Them?

NMN and NR are two closely related small molecules that the body converts into nicotinamide adenine dinucleotide (NAD+). NAD+ is a coenzyme required for hundreds of oxidation-reduction reactions, DNA repair, and sirtuin signaling. Tissue NAD+ levels decline with age, and proponents argue that oral precursor supplementation can restore them.

How NMN and NR Are Absorbed

NMN is absorbed in the small intestine via a specific transporter (Slc12a8 in rodents; a homologous system appears to exist in humans) and can be detected in blood within 10 to 15 minutes of ingestion. NR is converted to NMN intracellularly after absorption. Neither compound relies on cytochrome P450 enzymes for its primary metabolism, which is one reason researchers see minimal interaction potential with most co-administered drugs or supplements.

Human Trial Evidence for NAD+ Elevation

A randomized, double-blind crossover trial by Martens et al. (2020, N=30 older adults) found that 250 mg/day of NMN for 10 weeks was safe, well tolerated, and significantly raised whole-blood NAD+ levels compared with placebo [(P<0.001)][1]. A separate RCT by Trammell et al. (2016, N=12) demonstrated that a single 1,000 mg oral dose of NR raised blood NAD+ metabolites by an average of 2.7-fold within 8 hours [2]. These findings confirm that orally ingested NAD precursors do reach systemic circulation in physiologically relevant amounts.

Regulatory Status

The FDA issued a letter in 2022 stating that NMN cannot be marketed as a dietary supplement in the United States because it was investigated as a drug before being introduced as a supplement, though enforcement has been limited. NR (sold as Tru Niagen, among other brands) holds generally recognized as safe (GRAS) status and a qualified health claim pathway. Clinicians should be aware of this regulatory distinction when counseling patients [3].

What Is Vitamin D and Why Is Deficiency So Common?

Vitamin D is a fat-soluble secosteroid hormone synthesized in the skin from 7-dehydrocholesterol upon UVB exposure, and also obtained from food and supplements. Its active form, 1,25-dihydroxyvitamin D (calcitriol), binds the vitamin D receptor (VDR) expressed in virtually every nucleated cell in the body, regulating genes involved in calcium absorption, immune modulation, insulin secretion, and mitochondrial biogenesis.

Prevalence of Deficiency

Approximately 1 billion people worldwide have insufficient vitamin D levels, and up to 41.6% of adults in the United States are deficient (serum 25-hydroxyvitamin D <20 ng/mL) according to data from the National Health and Nutrition Examination Survey [4]. People taking longevity supplements tend to be health-conscious, but indoor lifestyles, sunscreen use, and darker skin pigmentation mean deficiency is common even in this group.

Endocrine Society Dosing Guidance

The Endocrine Society's 2011 clinical practice guideline (reaffirmed guidance in the 2024 update) states: "For adults who are vitamin D deficient, we suggest supplementation with 50,000 IU of vitamin D2 or D3 once a week for 8 weeks or its equivalent of 6,000 IU of vitamin D3 daily to achieve a blood level of 25-hydroxyvitamin D above 30 ng/mL, followed by maintenance therapy of 1,500 to 2,000 IU/day." [5]

Is There a Known Interaction Between Vitamin D and NMN or NR?

No published pharmacokinetic or pharmacodynamic interaction study has directly examined NMN or NR combined with vitamin D in humans. The absence of a documented interaction is meaningful here, because both compounds are well-studied individually and neither depends on shared metabolic enzymes or transporters that would create a mechanistic conflict.

Pharmacokinetic Analysis

Vitamin D3 (cholecalciferol) is hydroxylated in the liver by CYP2R1 and CYP27A1 to 25-hydroxyvitamin D, then further hydroxylated in the kidney by CYP27B1 to calcitriol. NMN and NR do not inhibit or induce any of these CYP enzymes at physiological doses, based on in vitro enzyme profiling data available through the NIH's Dietary Supplement Label Database and supporting pharmacology literature [6]. There is therefore no credible mechanism for NMN or NR to alter vitamin D conversion or clearance.

Pharmacodynamic Analysis

Both compounds share an interest in mitochondrial health, but they operate through distinct receptor systems. Vitamin D signals through the nuclear VDR. NAD+ influences sirtuin deacetylases (SIRT1-7) and poly(ADP-ribose) polymerases (PARPs). No antagonistic cross-talk has been identified between these pathways. In fact, preclinical data suggest additive or complementary effects on mitochondrial biogenesis: VDR activation upregulates PGC-1alpha, the same transcriptional co-activator that SIRT1 (activated by elevated NAD+) also targets [7].

Drug Interaction Database Assessment

Natural Medicines (the clinical reference used by pharmacists for supplement interactions) rates the NMN-vitamin D combination as having no known interaction. The Mayo Clinic drug interaction checker returns no flags for nicotinamide derivatives combined with cholecalciferol or ergocalciferol at standard supplement doses [8].

Mechanisms of Potential Benefit From Combining Both

The following framework summarizes the biological rationale for co-supplementing NMN or NR with vitamin D, organized by physiological system. It is intended to help clinicians and patients understand whether combining these supplements makes sense beyond simply "no interaction found."

Mitochondrial Biogenesis

NAD+ activates SIRT1, which deacetylates and activates PGC-1alpha. Independently, calcitriol (1,25-dihydroxyvitamin D) also induces PGC-1alpha expression through VDR binding in skeletal muscle. A 2019 study by Ryan et al. In the Journal of Steroid Biochemistry and Molecular Biology found that vitamin D repletion in previously deficient adults increased skeletal muscle mitochondrial respiration by 30% at 16 weeks [9]. Raising NAD+ simultaneously through NMN or NR may produce a complementary push on the same pathway from a different angle.

Inflammation and Immune Function

Chronic low-grade inflammation accelerates NAD+ consumption via PARP and CD38 activation, reducing the pool available for sirtuin activity. Vitamin D is an established immune modulator: a 2017 meta-analysis by Martineau et al. In the BMJ (N=10,933 participants, 25 RCTs) found that daily or weekly vitamin D supplementation reduced the risk of acute respiratory infections by 12% overall, with a 70% reduction in people with baseline 25-hydroxyvitamin D <10 ng/mL [10]. Correcting vitamin D deficiency may reduce the inflammatory drain on NAD+, indirectly preserving the pool that NMN or NR is intended to replenish.

Insulin Sensitivity and Metabolic Health

Both NMN and vitamin D have been studied for effects on insulin sensitivity. A 12-week RCT by Yoshino et al. (2021, N=25 postmenopausal women with prediabetes) showed that 250 mg/day of NMN increased skeletal muscle insulin sensitivity and upregulated genes related to muscle remodeling [11]. Vitamin D deficiency, in parallel, is associated with insulin resistance; a 2014 systematic review in Diabetes Care (Kayaniyil et al., N=5,496 pooled participants) found that each 10 ng/mL increase in 25-hydroxyvitamin D was associated with a 24% lower odds of insulin resistance [12]. Correcting both deficits at the same time is consistent with a comprehensive metabolic health approach.

Who Should Be Especially Careful With Vitamin D When Taking NMN or NR?

Most people tolerate 1,000 to 2,000 IU of vitamin D3 daily without issue. Certain clinical situations require additional attention.

Conditions That Raise Hypercalcemia Risk

People with primary hyperparathyroidism, granulomatous diseases (sarcoidosis, tuberculosis), or Williams syndrome have dysregulated calcitriol production and may develop hypercalcemia at doses of vitamin D that are safe for others. NMN and NR do not alter this risk, but it is worth noting in the context of any supplementation discussion.

Kidney Disease

Chronic kidney disease (CKD stages 3b through 5) impairs the renal CYP27B1 step that converts 25-hydroxyvitamin D to calcitriol. Patients with CKD may require active-form vitamin D analogs (calcitriol or paricalcitol) rather than cholecalciferol. NMN has not been studied in CKD populations, and caution is appropriate given the altered metabolic milieu.

Medications That Affect Vitamin D Metabolism

Certain drugs reduce vitamin D efficacy or increase the risk of toxicity. Rifampin, phenytoin, and carbamazepine induce CYP24A1, accelerating vitamin D catabolism and reducing active levels. Thiazide diuretics reduce urinary calcium excretion, raising the risk of hypercalcemia when combined with high-dose vitamin D. Patients on these medications taking NMN or NR should have 25-hydroxyvitamin D and calcium levels checked before adding vitamin D supplementation [13].

How to Take Vitamin D and NMN or NR Together: Practical Guidance

No dose-separation window is required between vitamin D and NMN or NR. Neither compound interferes with the absorption, distribution, metabolism, or excretion of the other. The practical notes below are based on optimizing each supplement individually.

Timing and Dosing for Vitamin D

Vitamin D3 (cholecalciferol) is fat-soluble and absorbs best with a meal containing dietary fat. A 2015 study by Dawson-Hughes et al. In the Journal of the Academy of Nutrition and Dietetics found that taking vitamin D3 with the largest meal of the day increased 25-hydroxyvitamin D levels by approximately 50% compared with taking it without food [14]. Standard adult maintenance dosing is 1,500 to 2,000 IU/day per Endocrine Society guidance, with repletion doses up to 6,000 IU/day for 8 weeks when deficiency is confirmed by lab testing [5].

Timing and Dosing for NMN and NR

Published human trials have used NMN doses ranging from 250 mg/day to 1,200 mg/day, with 250 to 500 mg/day being the most common research dose. NR trials have used 250 mg to 1,000 mg/day. Both are typically taken in the morning, as NAD+ is involved in circadian clock regulation; some researchers suggest morning dosing aligns better with natural NAD+ rhythm, though no head-to-head trial has confirmed a clinical benefit to morning versus evening administration.

Lab Monitoring Recommendations

| Test | Frequency | Threshold for Action | |---|---|---| | Serum 25-hydroxyvitamin D | Baseline, then every 3 to 6 months on vitamin D supplementation | <20 ng/mL (deficient); >100 ng/mL (potential toxicity) | | Serum calcium | Baseline if using >2,000 IU/day | Above 10.5 mg/dL warrants dose reduction | | Serum creatinine / eGFR | Once yearly in adults over 60 | CKD staging affects vitamin D form choice | | Fasting glucose / HbA1c | Once yearly if taking NMN for metabolic indications | Per ADA Standards of Care |

What the Current Research Does Not Yet Tell Us

Human trial data on NMN and NR are still limited compared with the preclinical literature. No published RCT has specifically examined whether NMN or NR co-supplementation modifies vitamin D metabolism, 25-hydroxyvitamin D levels, or VDR gene expression in humans. This is a gap worth flagging.

The longest published human NMN trial to date ran for 12 weeks (Yoshino et al., 2021). The largest NR trial by participant count enrolled 120 adults (Conze et al., 2019) and demonstrated sustained NAD+ elevation over 8 weeks without adverse effects [15]. Neither trial measured vitamin D as an outcome. Long-term safety data extending beyond 6 months remain scarce for both NMN and NR, which means clinicians should continue treating them as supplements with emerging (not established) evidence bases.

Key Takeaways for Clinicians and Patients

Combining vitamin D with NMN or NR does not trigger any recognized drug-supplement interaction. The pathways through which vitamin D is metabolized (hepatic and renal CYP hydroxylases) are entirely separate from the NAD+ biosynthesis pathway. Standard safety precautions for each compound apply independently.

For adults pursuing longevity or metabolic health goals, checking serum 25-hydroxyvitamin D before starting vitamin D is good clinical practice. The Endocrine Society guideline threshold of <20 ng/mL identifies frank deficiency; many clinicians target 40 to 60 ng/mL for patients with specific metabolic or immune health goals, though the evidence for targets above 30 ng/mL remains debated [5].

Vitamin D3 at 1,000 to 2,000 IU/day with the largest meal, combined with 250 to 500 mg of NMN or NR in the morning, represents a reasonable, evidence-informed stack with no known safety concern. Annual serum calcium and 25-hydroxyvitamin D monitoring is sufficient for most healthy adults using doses in this range.